SCHEMBL25369907

SCHEMBL25369907

CNC(=O)c1ccc(NC(=O)c2csc(C(=O)Nc3cccc(NS(C)(=O)=O)c3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.56
▸ KDM4E B2RXH2 3/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ DHX9 Q08211 1/20 0.48
▸ NAMPT P43490 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ KCNK3 O14649 1/20 0.44
▸ KCNK9 Q9NPC2 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PHGDH O43175 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543946 0.90 DHX9 (0.53) HPGDKDM4ETDP1DHX9LMNA
SCHEMBL25368280 0.90 DHX9 (0.53) HPGDKDM4ETDP1DHX9LMNA
SCHEMBL25368554 0.89 HPGD (0.53) HPGDKDM4ETDP1DHX9NAMPT
SCHEMBL25368447 0.88 HPGD (0.51) HPGDKDM4ETDP1DHX9LMNA
SCHEMBL25368657 0.87 HPGD (0.51) HPGDKDM4ETDP1DHX9NAMPT
SCHEMBL25368034 0.86 KMT2A (0.60) HPGDDHX9LMNAALDH1A1SMN1; SMN2
SCHEMBL25369304 0.85 DHX9 (0.52) HPGDKDM4ETDP1DHX9NAMPT
SCHEMBL30544037 0.85 DHX9 (0.52) HPGDKDM4ETDP1DHX9NAMPT
SCHEMBL25367472 0.84 MEN1 (0.53) HPGDKDM4ETDP1DHX9ALDH1A1
SCHEMBL25368564 0.84 KDM4E (0.48) HPGDKDM4ETDP1DHX9NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B HPGD 852/4885KDM4E 1934/4885TDP1 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback